Skip to content
FORSIDEN
Log ind Opret konto
  • Kategorier
  • Seneste
  • Etiketter
  • Populære
  • Verden
  • Bruger
  • Grupper
Temaer
  • Light
  • Brite
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Kollaps
  1. Debatforum
  2. Kategorier
  3. Genmab
  4. Genmab — December 2024

Genmab — December 2024

Planlagt Fastgjort Låst Flyttet Genmab
476 Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • E Offline
    E Offline
    E_L
    wrote on sidst redigeret af
    #28

    In hindsight, it would have been better if we had gotten bored of Genmab and become more silent here 2 years ago and sold the lot at 3000... In that light you should even be angry at all the writers for posting too much 😉

    1 Reply Last reply
    0
    • E Offline
      E Offline
      E_L
      wrote on sidst redigeret af
      #29

      Bispecific antibodies targeting BCMA or GPRC5D are highly effective in relapsed myeloma after CAR T-cell therapy https://www.nature.com/articles/s41408-024-01197-2

      1 Reply Last reply
      0
      • DarvinD Offline
        DarvinD Offline
        Darvin
        wrote on sidst redigeret af
        #30

        😉

        1 Reply Last reply
        0
        • SolsenS Offline
          SolsenS Offline
          Solsen
          wrote on sidst redigeret af
          #31

          Imponerende data på tec og tal efter CAR-t relapse !

          1 Reply Last reply
          0
          • G Offline
            G Offline
            gentogen
            wrote on sidst redigeret af
            #32

            Uanset hvad vil jeg også gerne sige tusind tak EL for de mange informationer om Genmab. Som Solsen lige skrev, så er blot den sidste artikel jo monster interessant. Og der er sikkert andre end mig, der læser alle dine links, selv om vi er godt trætte af at vente på hexen...

            1 Reply Last reply
            0
            • L Offline
              L Offline
              lahn1
              wrote on sidst redigeret af
              #33

              EL, you know we like your news bulletin.

              1 Reply Last reply
              0
              • P Offline
                P Offline
                ProinvestorNEWS
                wrote on sidst redigeret af
                #34

                I videoen her gennemgår vi Genmab med 3-PointPlaybook-strategien. Her kigger vi på følgende punkter:

                1. Er aktien solid?
                2. Er aktien godt prissat?
                3. Er timingen rigtig? https://proinvestor.com/boards/123320
                1 Reply Last reply
                0
                • E Offline
                  E Offline
                  E_L
                  wrote on sidst redigeret af
                  #35

                  Japanese acasunlimab safety trial Completed https://clinicaltrials.gov/study/NCT04937153?tab=history&a=17&b=18&compareMode=sideBySide#version-content-panel

                  1 Reply Last reply
                  0
                  • E Offline
                    E Offline
                    E_L
                    wrote on sidst redigeret af
                    #36

                    https://x.com/Larvol/status/1864673303862157521/photo/1 promising #ClinicalTrials, most discussed among the oncologists on X - TRIMM-2 = Talq-Dara, Epcore= Epco, MajesTEC=Teclistamab, Auriga & AQUILA =Dara

                    1 Reply Last reply
                    0
                    • P Offline
                      P Offline
                      ProinvestorNEWS
                      wrote on sidst redigeret af
                      #37

                      Danmark har flere store virksomheder, som danskerne er stolte af, og som er blevet til folkeaktier. Men det seneste års tid har der været udfordringer, som har fået nogle danskere til at søge grønnere græsgange. Lyt med, når Helge Larsen kigger på udfordringerne hos to af folkeaktierne - nemlig Vestas og Genmab. https://proinvestor.com/boards/123323

                      1 Reply Last reply
                      0
                      • P Offline
                        P Offline
                        ProinvestorNEWS
                        wrote on sidst redigeret af
                        #38

                        Teknisk analyse på Genmab https://proinvestor.com/boards/123349

                        1 Reply Last reply
                        0
                        • BulderB Offline
                          BulderB Offline
                          Bulder
                          wrote on sidst redigeret af
                          #39

                          En fair value, der er til at forstå 😉 https://simplywall.st/stocks/dk/pharmaceuticals-biotech/cph-gmab/genmab-shares

                          1 Reply Last reply
                          0
                          • M Offline
                            M Offline
                            M_T_A
                            wrote on sidst redigeret af
                            #40

                            @Bulder hehe, synes dog tit at Simplty har værdiansættelser helt hen i vejret. 🙂 Kigger man på forudsætningerne fra beregningen antager beregningen en FCF på nuværende 6 mia som vokser til underkanten af 20 mia i 2030, og fortsætter i samme tempo. Er dette en realistisk projektion? Hmm 😄

                            1 Reply Last reply
                            0
                            • R Offline
                              R Offline
                              Riis7
                              wrote on sidst redigeret af
                              #41

                              Det hvis os bare en omgang ai de bruger;-) måske sælge Genmab og købe nogle ai aktier 😉 nvidia har vækst;-)

                              1 Reply Last reply
                              0
                              • D Offline
                                D Offline
                                deleted-user
                                wrote on sidst redigeret af
                                #42

                                Jeg bliver altid så glad, når jeg læser dine indlæg Riis. Det minder mig om, at Proinvestor har plads til alle.

                                1 Reply Last reply
                                0
                                • E Offline
                                  E Offline
                                  E_L
                                  wrote on sidst redigeret af
                                  #43

                                  Genmab
                                  @Genmab
                                  We are presenting new clinical data at #ASH24 across subtypes of non-Hodgkin’s lymphoma (#NHL), a type of cancer that affects the lymphatic system, usually found in the lymph nodes. Swipe to learn more about this disease and how it can affect patients.
                                  https://x.com/Genmab/status/1865097213652668441

                                  1 Reply Last reply
                                  0
                                  • E Offline
                                    E Offline
                                    E_L
                                    wrote on sidst redigeret af
                                    #44

                                    Link Preview Image

                                    favicon

                                    X (formerly Twitter) (x.com)

                                    1 Reply Last reply
                                    0
                                    • HenrikhotH Offline
                                      HenrikhotH Offline
                                      Henrikhot
                                      wrote on sidst redigeret af
                                      #45

                                      Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Therapy Demonstrates High Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL). https://ir.genmab.com/news-releases/news-release-details/investigational-epcoritamab-duobodyr-cd3xcd20-combination https://ir.genmab.com/news-releases/news-release-details/investigational-epcoritamab-duobodyr-cd3xcd20-combination

                                      1 Reply Last reply
                                      0
                                      • SolsenS Offline
                                        SolsenS Offline
                                        Solsen
                                        wrote on sidst redigeret af
                                        #46

                                        2 års overlevelse i FL relapsed er 90% og er imponerende. Epco bliver et stort aktiv.

                                        1 Reply Last reply
                                        0
                                        • E Offline
                                          E Offline
                                          E_L
                                          wrote on sidst redigeret af
                                          #47

                                          the press release from AbbVie -- https://news.abbvie.com/2024-12-07-Investigational-Epcoritamab-DuoBody-R-CD3xCD20-Combination-Therapy-Shows-High-Response-Rates-in-Clinical-Trial-of-Patients-With-Relapsed-or-Refractory-R-R-Follicular-Lymphoma-FL

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind
                                          Svar
                                          • Svar som emne
                                          Login for at svare
                                          • Ældste til nyeste
                                          • Nyeste til ældste
                                          • Most Votes


                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          Powered by NodeBB Contributors
                                          • First post
                                            Last post
                                          0
                                          • Kategorier
                                          • Seneste
                                          • Etiketter
                                          • Populære
                                          • Verden
                                          • Bruger
                                          • Grupper